AN DER GOLDGRUBE 12, MAINZ, 2M
Provides Update on Phase 2 Clinical Trial of Autogene Cevumeran in Resected Colorectal Cancer
Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
Material disclosure
Development Update and Financial Results for the Three and Six Months Ended June 30, 2026
Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
Disclosure of Share Buyback Program Pursuant to Art. 5(1) Lit. A) of the Regulation (EU) No. 596/2014 and Art. 2(1) of the Delegated Regulation (EU) 2016/1052
Global Data for and’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
Amended Annual and Transition Report of Foreign Private Issuers
Annual and Transition Report of Foreign Private Issuers
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
Tender Offer Statement by Third Party
No filings found
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Tender Offer Statement by Third Party
Amended Notice of Proposed Sale of Securities
S-8 POS